ArticleClinical and experimental medicine2026
Global, regional, and national burden and future projections of pancreatitis: A Joinpoint, APC, and ARIMA modeling analysis.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Persistence of Mortality-Dominant Pancreatitis Burden Despite Declining Rates, 1990-2023: An Analysis of the Global Burden of Disease 2023 Study.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- C-reactive protein-triglyceride-glucose index predicts acute pancreatitis severity: a retrospective cross-sectional study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatitis is a serious worldwide public health concern, with a currently increasing disease burden. Up-to-date information on pancreatitis burden can provide new strategies for its screening, diagnosis, treatment, and rational allocation of resources. Based on the Global Burden of Diseases (GBD) 2021, this study estimated the number of cases, age-standardized rates (ASRs) per 100,000 population, and risk factors of pancreatitis in 204 countries and regions. Joinpoint regression analysis was used to calculate the Average Annual Percentage Changes (AAPCs) in the incidence, mortality, and Disability-Adjusted Life Years (DALYs) of pancreatitis. In comparison to GBD 2017 and 2019, our analysis based on GBD 2021 reveals new epidemiological trends in pancreatitis. Eastern Europe has surpassed other regions (notably overtaking previously leading North America) and recorded the highest age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) in 2021. ASIR and ASDR in high-middle social demographic index (SDI) regions have increased compared with earlier estimates, whereas both rates showed a marked decline in high-SDI regions. In addition, males were disproportionately affected (ASIR 36.75 vs. 28.82 per 100,000), consistent with higher alcohol exposure among men. Notably, Eastern Europe has surpassed North America to become the region with the highest ASIR and ASMR of pancreatitis. Furthermore, projections for the next 15 years indicate that the incidence rate will gradually decrease in men but is expected to increase in women. Pancreatitis poses a high public health burden globally and has significant regional differences. These regional and population differences are constantly changing over time, which is essential for developing focused public health interventions and policies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.